Conference abstract · 23 Jun 2025
Conference abstractPublished 7 Dec 2015
Observation of clinico-epidemiological and immune status of HIV/AIDS patients of Bangladesh
Bangabandhu Sheikh Mujib Medical University, Bangladesh
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: The management of HIV/AIDS in Bangladesh has been greatly transformed because of widespread availability of anti-retroviral Therapy (ART). The present study was undertaken to determine the clinico-epidemiological and immune monitoring among the Bangladeshi HIV/AIDS patients. Methods: A cross-sectional study was carried out among 100 HIV/AIDS patients divided into Therapy naAÃ?¯ve (Group I; n=33), Symptomatic Therapy naAÃ?¯ve (Group II; n=33) and ART receivers >1 year (Group III; n=34) at the Department of Virology of Bangabandhu Sheikh Mujib Medical University (BSMMU) between January and December of 2011. Patients were monitored during their clinical follow-ups and CD4 & CD8 T-lymphocyte were analyzed using Flow cytometer (BD FACS count, USA). Results: Of the 100 HIV/AIDS patients, 53 (53%) were males, 43 (43%) were females and 4 (4%) were trans-genders (TGs). The age of the study population ranged from 19 to 60 years (meanAÃ?±SD; 33.53AÃ?±9.07 years) with predominant age group between 30-40 years. The most frequent (84%) mode of transmission was heterosexual route. 76% of Group I and 91% of Group III were asymptomatic as per their clinical presentation. Among Group II, majority (58%) of individuals were presented with a combination of fever, diarrhea, weight loss and oral infection. As per WHO Clinical stagingÃ?¢Ã?Â?Ã?Â?s, 81% of Group I were belong to Stage 1, whereas, in Group II, 42% and 36% were belong to Stage 3 and Stage 4 respectively. CD4 and CD8 T-lymphocyte were 591AÃ?±217 and 1266AÃ?±433 cells/IÃ?¼l respectively in Group I. Among Group II, CD4 T-lymphocyte were found reduced significantly to 155AÃ?±127 cell/IÃ?¼l (P<0.05) while CD8 T-lymphocyte were 758AÃ?±564 cell/IÃ?¼l (P<0.05) when compared with Group I. Among Group III, CD4 and CD8 T-lymphocyte count were 588AÃ?±228 and 1104AÃ?±417 cells/IÃ?¼l respectively with no significant difference with Group I suggesting the intake of ART has prominently bring back the immune function to near normal. All the symptomatic therapy naAÃ?¯ves with CD4 T-lymphocyte count <350 cells/IÃ?¼l were subsequently counseled for ART program. Conclusion: Timely initiation of ART and clinical/immune follow-up ensures the success of the ongoing national scale up of the ART Program in Bangladesh.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Antivirals & Antiretrovirals.
Conference abstract · 23 Jun 2025
Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach
Conference abstract · 23 Jun 2025
Correlation Between the Rh/ABO system and infection due to sars cov2 in morocco
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “S M Rashed-ul Islam”
- BylineArticles whose byline prints “Shahina Tabassum”
